
Opinion|Videos|May 28, 2025
Clinical Insights Into Managing Heavily Pretreated HER2+ Metastatic Breast Cancer
Panelists discuss how they approach treatment beyond third-line therapy for HER2-positive (HER2+) metastatic breast cancer, considering factors such as prior therapies, residual toxicities, and patient preferences when selecting from multiple options.
Advertisement
Episodes in this series

Clinical Brief: Beyond Third-Line Therapy in HER2+ Metastatic Breast Cancer
Key Themes:
- Clinical Trial Priority: Enrollment in clinical trials is ideal for heavily pretreated patients
- Fourth-Line Options: If the HER2CLIMB regimen is used in the third line, T-DM1 becomes a preferred fourth-line option
- Personalized Selection Factors: Prior treatments, residual toxicities, and patient preferences guide therapy selection in later lines
Key Points for Physicians:
- Multiple guideline-supported options exist beyond the third line, including taxanes with trastuzumab, capecitabine with trastuzumab or lapatinib, margetuximab, and others
- Consider residual toxicities when selecting later-line therapy (eg, avoid taxanes with significant neuropathy)
- Limited clinical experience exists with sequential tyrosine kinase inhibitor (TKI) use (eg, neratinib after tucatinib)
- Novel agents in clinical trials include new antibody-drug conjugates and bispecific antibodies
Notable Insights:
- Decision-making becomes highly nuanced in later lines of therapy
- Despite multiple theoretical options, some agents such as margetuximab have limited real-world adoption
- The theoretical rationale for sequential TKI use based on specificity profiles has not been widely tested in practice
Clinical Significance:
Beyond third-line therapy for HER2+ metastatic breast cancer, treatment selection becomes increasingly individualized based on prior treatments, toxicity profiles, and patient preferences, with clinical trials offering the most promising opportunities for heavily pretreated patients.
Advertisement
Related to this article

Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.

Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma
3
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma
4
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
5

